SCHEMBL5367356

SCHEMBL5367356

CC(C)(C)C(=O)Oc1c(I)cc(-c2ccc(F)cc2F)cc1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.60
ACMSD Q8TDX5 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
DHFR P00374 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
LMNA P02545 1/20 0.48
ALB P02768 1/20 0.48
HMGB1 P09429 1/20 0.48
HPGD P15428 1/20 0.48
CXCL12 P48061 1/20 0.48
KMT2A Q03164 1/20 0.48
HIF1A Q16665 1/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DHODH Q02127 4/20 0.40
EIF4E P06730 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369440 0.84 TTR (0.67) TTRACMSDKDM4EMEN1USP2
SCHEMBL5373309 0.84 TTR (0.60) TTRACMSDKDM4EMEN1USP2
SCHEMBL19294158 0.80 TTR (0.58) TTRACMSDKDM4EMEN1USP2
SCHEMBL14408188 0.77 TTR (0.72) TTRACMSDKDM4EMEN1USP2
SCHEMBL5380998 0.76 TTR (1.00) TTRACMSDKDM4EMEN1USP2
SCHEMBL29377136 0.76 TTR (1.00) TTRACMSDKDM4EMEN1USP2
SCHEMBL5371406 0.73 TTR (0.49) TTRACMSDKDM4EMEN1USP2
SCHEMBL14408189 0.72 TTR (0.51) TTRACMSDKDM4EMEN1USP2
SCHEMBL14446936 0.72 TTR (0.51) TTRACMSDKDM4EMEN1USP2
SCHEMBL5371499 0.71 TTR (0.55) TTRACMSDKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265245-B2 Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils INNOVAPROTEAN, S.L (ES) 2007-09-04 US claimed
US-20070167378-A1 COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS INNOVAPROTEAN, S.L. (ES) 2007-07-19 US claimed
EP-1679299-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS Innovaprotean, S.L. (ES) 2006-07-12 EP claimed
US-7265245-B2 Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils INNOVAPROTEAN, S.L (ES) 2007-09-04 US disclosed
US-20070167378-A1 COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS INNOVAPROTEAN, S.L. (ES) 2007-07-19 US disclosed
EP-1679299-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS Innovaprotean, S.L. (ES) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167378-A1 COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS APP, C1R, RTN3 TTR 12/4885ACMSD 553/4885KDM4E 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.